ClinicalTrials.gg
Not yet recruitingNCT07453394Updated Mar 6, 2026

QLS5132 Combination Therapy in Advanced Solid Tumors

A Phase 1/2 interventional study of QLS5132; Bevacizumab and QLS5132; Platinum; Bevacizumab in Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) and Endometrial Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
626
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing bevacizumab in Stomach Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Bevacizumab · Stomach Neoplasms.

Planned enrollment
Largest of 22
626 · median 44
Started
2026
with 1 other
Phase 1/2
2 of 23
2 open now
Registered
23rd of 23
by date

Among the 23 studies testing bevacizumab in Stomach Neoplasms, this one has the largest planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 1/2, and was the 23rd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

3 of the 23 studies testing bevacizumab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing bevacizumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion.

The main questions it aims to answer are:

  • In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5132 combination therapy, and what are the recommended dose(s) for expansion?
  • In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5132 combination therapy at the selected dose(s) in participants with specific tumor types?

Participants will:

  • Be enrolled in sequential cohorts to receive QLS5132 in combination with other anticancer agents.
  • Undergo regular assessments for safety, drug concentration levels (PK), and tumor response.
03

Conditions studied

  • Gastric Cancer (GC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Endometrial Cancer
  • Advanced Solid Tumors
  • Ovarian Cancer

Keywords

  • CLDN6 ADC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Advanced solid tumors;
  2. , per (RECIST) version 1.1 (v1.1);
  3. (ECOG) performance status 0-1;
  4. Adequate organ function;
  5. Recover from all reversible AEs from previous anti-tumor treatment (i.e., Grade ≤ 1, according to National Cancer Institute- [NCI-CTCAE] v5.0), excluding alopecia (any grade) and Grade ≤ 2 neuropathy peripheral.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with drugs targeting CLDN6 (including antibody-drug conjugates [ADCs]), or any drug containing topoisomerase I inhibitors (including ADCs);
  2. Received prior chemotherapeutic, , or other therapies for the treatment of cancer within 2 weeks with small molecule and within 4 weeks with biologic before the first dose of QLS5132;
  3. Progressive or symptomatic ;
  4. Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection;
  5. History of significant cardiac disease, or poorly controlled diabetes mellitus;
  6. History of recurrent diseases;
  7. History of myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia (AML);
  8. History of a second primary ;
  9. If female, is pregnant or breastfeeding;
  10. Be allergic to any component of QLS5132 or its .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
626 participants (estimated)

Study arms

  • Experimental
    QLS5132 combined wtih bevacizumab

    QLS5132 in combination with bevacizumab

    Drug: QLS5132; Bevacizumab

  • Experimental
    QLS5132 combined wtih platinum

    QLS5132 in combination with platinum, followed by sequential QLS5132 alone or in combination with bevacizumab

    Drug: QLS5132; Platinum; Bevacizumab

  • Experimental
    QLS5132 combined wtih Olaparib

    QLS5132 in combination with Olaparib, followed by sequential QLS5132 alone or in combination with bevacizumab

    Drug: QLS5132; Olaparib; Bevacizumab

  • Experimental
    QLS5132 combined wtih immune checkpoint inhibitors

    QLS5132 in combination with immune checkpoint inhibitors

    Drug: QLS5132; QL1706; QL2107

  • Experimental
    QLS5132 combined with immune checkpoint inhibitors and chemotherapy

    QLS5132 in combination with immune checkpoint inhibitors and chemotherapy

    Drug: QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events

    Incidence and severity of adverse events

    Time frame: up to 2 years

  2. Maximum tolerated dose (MTD)

    Highest administered dose with \< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants

    Time frame: From basline to Day 28

  3. Recommended Phase 2 Dose (RP2D)

    Time frame: up to 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

Of 89 industry-sponsored phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 109. This study's planned 12 months is below that.

Counting every sponsor, half of 156 studies reached it within 60 months; a quarter within 41 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2026
First posted
Mar 6, 2026
StartEst.
Apr 2026
Primary completionEst.
Apr 2027
CompletionEst.
Feb 2029
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07453394
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Apr 2026 (estimated)
Primary completion
Apr 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Mar 6, 2026

Study contacts

Tao Zhu, PhD
Contact
zhutao@zjcc.org.cn
+86 13858065156

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: QLS5132 · Bevacizumab · Platinum Compounds · Olaparib · QL2107

Start the discussion